ASX/Media RELEASE 10 September 2007
pSivida to present at the Astrologers Fund Conference in
New York City
Boston, MA and Perth, Australia (September 10, 2007) – Global Drug Delivery Company, pSivida
Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that the Company’s Vice President,
Investor Relations, Mr Brian Leedman will be making a company presentation at the Astrologers Fund
Conference for Emerging Hi-Growth Sectors at the Princeton Club, NYC, 1pm US EST on Tuesday,
September 11th, 2007. The Company will be providing an update on the recent activities and goals
moving forward.
The Astrologers Fund Hi-Growth Sectors Conference features emerging and quality investment
opportunities in attractive small, mid and microcap companies. Details about this conference can be
obtained by going to the website link below:
http://www.afund.com/fallinvest2007.html?
The Company's presentation will not be webcast but can be viewed at the website link below:
http://www.psivida.com/News/Presentations.asp
Released by:
pSivida Limited
Brian Leedman
Vice President, Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099
[email protected]
US Public Relations
Beverly Jedynak
President
Martin E. Janis & Company, Inc
Tel: +1 (312) 943 1100 ext. 12
[email protected]
European Public Relations
Eva Reuter
Accent Marketing Limited
Tel: +49 (254) 393 0740
[email protected]
NOTES TO EDITORS:
pSivida is a global drug delivery company committed to the biomedical sector and the development of drug delivery products.
Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV
Retinitis. Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. pSivida has licensed the technologies underlying both
of these products to Bausch & Lomb. The technology underlying Medidur™ for diabetic macular edema is licensed to Alimera
Sciences and is in Phase III clinical trials. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc.
for other ophthalmic applications of the Medidur™ technology.
pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as
BioSilicon™, which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced
BioSilicon™ product, BrachySil™ delivers a therapeutic, P32 directly to solid tumors and is presently in Phase II clinical trials for
the treatment of pancreatic cancer.
pSivida’s intellectual property portfolio consists of 71 patent families, 99 granted patents, including patents accepted for
issuance, and over 300 patent applications. pSivida conducts its operations from facilities near Boston in the United States,
Malvern in the United Kingdom and Perth in Australia.
pSivida is listed on NASDAQ (PSDV), the Australian Stock Exchange (PSD) and on the Frankfurt Stock Exchange on the
XETRA system (PSI). pSivida is a founding member of the NASDAQ Health Care Index and the Merrill Lynch Nanotechnology
Index.
This release contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations
reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will
prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many
important factors that are contained in cautionary statements in the Annual Report on Form 20-F filed with the U.S. Securities
and Exchange Commission, including, without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to update
any oral or written forward-looking statements that may be made by or on behalf of pSivida.
PSD
psivida limited
